NCT00328211View on ClinicalTrials.gov

Intralumenal Effects on Cholesterol Absorption/Synthesis

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)

15 mg/kg/day for 18 days

DIETARY_SUPPLEMENT

Sphingomyelin

1000mg/day for 19 days

OTHER

C13 Stable isotope of Cholesterol

Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT00328211 - Intralumenal Effects on Cholesterol Absorption/Synthesis | Biotech Hunter | Biotech Hunter